Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stoke Therapeutics (STOK – Research Report), Novavax (NVAX – Research Report) ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax is set to release its quarterly earnings on May 9, 2025, with analysts expecting earnings per share of $0.19 and projected revenue of $204.1 million. The company’s recent multi-billion-dollar ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD- Utah study ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Shares of Novavax, Inc. (NVAX) traded 16% higher on Thursday morning after the company reported upbeat first-quarter (Q1) ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax stock is limping into earnings season. Its upcoming May 8 Q1 results might be the last shot at redemption. Once hailed as a pandemic hero, the biotech firm is now fighting ...